Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice

Takashi Tajiri, Hiroshi Yoshida, Yasuhiro Mamada, Nobuhiko Taniai, Shigeki Yokomuro, Yoshiaki Mizuguchi

Abstract
Cholangiocarcinoma is the second most common primary hepatic cancer. Despite advances in diagnostic techniques during the past decade, cholangiocarcinoma is usually encountered at an advanced stage. In this review, we describe the classification, diagnosis, and initial management of cholangiocarcinoma with obstructive jaundice.

© 2008 WJG. All rights reserved.

Key words: Cholangiocarcinoma; Obstructive jaundice; Diagnosis; Treatment; Initial management

INTRODUCTION
Cholangiocarcinoma is the second most common primary hepatic cancer. Despite advances in diagnostic techniques during the past decade, cholangiocarcinoma is usually encountered at an advanced stage. In this review, we describe the classification, diagnosis, and initial management of cholangiocarcinoma with obstructive jaundice.

CLASSIFICATION
Cholangiocarcinomas are epithelial neoplasms that originate from cholangiocytes and can occur at any level of the biliary tree. These lesions are broadly classified into intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, and distal extrahepatic bile duct tumors. Histologically, most cholangiocarcinomas (> 95%) are adenocarcinomas. They are pathologically classified into sclerosing, nodular, and papillary intraductal cancers. A recent pathological classification applicable to both intrahepatic and extrahepatic cholangiocarcinomas divides these lesions into mass-forming (nodular), periductal-infiltrating (sclerosing), and intraductal-growing (papillary) cholangiocarcinomas.

DIAGNOSIS

Laboratory data
Liver test abnormalities reflecting obstruction of the bile duct are usually observed. Strikingly elevated CA19-9 values in symptomatic patients usually signify advanced disease. Carcinoembryonic antigen (CEA) is also elevated in patients with cholangiocarcinoma, but is not diagnostic because of low sensitivity and specificity. Cholangitis and hepatolithiasis commonly lead to increased levels of tumor markers. Cholangiocarcinoma should not be diagnosed on the basis of laboratory data alone.

Ultrasoundography
Ultrasoundography is the imaging technique of choice for the diagnosis of cholangiocarcinoma with obstructive jaundice. Visualization allows adequate diagnosis and staging in more than 90% of cases. The presence of dilated ducts without clear communications within a liver lobe indicates the extension of tumor into the segmental bile ducts. Ultrasoundography is useful for evaluating the local extent of disease, but is of limited value for staging distant metastases. Intrahepatic cholangiocarcinomas may be identified as mass lesions, sometimes associated with bile duct dilatation proximal to the obstructing lesion. Tumor vascularity is an important characteristic that can be assessed by color Doppler ultrasonography. An abnormal pulsed Doppler signal obtained from the portal venous system due to severe narrowing or occlusion...
strongly suggests major involvement and unresectable tumor. However, a normal pulsed Doppler signal does not exclude such involvement, if the tumor is contiguous with vessels showing interruption of the hyperechoic tumor-vessel interface\[5,6\].

Endoscopic ultrasound (EUS) is useful for assessing the extent of disease and performing fine needle aspiration. Eloubeidi \textit{et al.}\[7\] reported that EUS-guided fine needle aspiration biopsy is useful for the diagnosis of suspected cholangiocarcinoma. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 86\%, 100\%, 100\%, 57\%, and 88\%, respectively. EUS-guided fine needle aspiration of lymph nodes facilitates staging of disease in addition to visualization of the biliary tree\[8\].

**Computed tomography (CT)**

CT permits the identification of bile duct dilatation and assessment of the hepatic parenchyma and lymph nodes. However, the evaluation of horizontal spread by diagnostic imaging via the bile duct remains challenging in patients with cholangiocarcinoma, especially on conventional CT examination. Recently, the development of multidetector row CT scanners has permitted a reduction in the voxel size and facilitated rapid image reconstruction, enhancing the value of CT as an interactive diagnostic tool. Moreover, innovative methods for CT image reconstruction, including multiplanar reconstruction and three-dimensional images, were recently introduced for the visualization of biliary structures\[9,10\]. CT angiography has been demonstrated to be useful for the detection and assessment of vascular encasement\[11,12\].

**Magnetic resonance imaging (MRI)**

MRI with concurrent magnetic resonance cholangio-pancreatography (MRCP) is the radiologic technique of choice for assessing the extent of disease\[13,14\]. The limitations of conventional imaging techniques have led to the increased use of MRCP, which is a noninvasive and highly accurate technique for the evaluation of patients with biliary obstruction. MRCP is optimally suited for the visualization of both intrahepatic and extrahepatic cholangiocarcinomas, which appear as hypointense lesions on T1-weighted images and hyperintense lesions on T2-weighted images. Images can be enhanced with the use of superparamagnetic iron or by delayed gadolinium enhancement\[15,16\]. The overall diagnostic accuracy for assessment of the level and cause of obstruction was 96.3\% and 89.7\%, respectively\[17\]. MR angiography can be used to evaluate vascular involvement\[18\].

**Cholangiography**

Before the development of MRCP, direct cholangiography was only technique for assessment of the biliary system. Direct cholangiography can be performed by either percutaneous transhepatic cholangiography or endoscopic retrograde cholangiography, and samples of the bile duct can be obtained\[19,20\]. Brushings are analyzed cytologically. In one study, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of brush cytology were 75\%, 100\%, 100\%, 12.5\%, and 75.9\%, respectively. Biopsy specimens of the bile duct are examined histologically\[21\]. The diagnostic performance of transluminal forceps biopsy for malignant biliary obstructions was as follows: sensitivity, 78.4\%; specificity, 100\%; and accuracy, 79.2\%\[22\]. Savader \textit{et al.}\[23\] compared the diagnostic accuracy of three different techniques for percutaneous transhepatic intraductal biopsy: brush cytology, clamshell forceps under choledochoscopic guidance, and clamshell forceps under fluoroscopic guidance. The choledochoscope-directed biopsy technique had the highest sensitivity and specificity among the three techniques, but was not significantly better than either the brush or fluoroscopic clamshell techniques (P > 0.10). Multiple biopsies did not increase the overall sensitivity of intraductal biliary biopsy as a diagnostic technique. All three techniques were safe and easy to perform. In patients with malignant biliary obstruction, brush cytology was more sensitive for the diagnosis of cholangiocarcinoma than for the diagnosis of non-cholangiocarcinoma (P < 0.05). The site of stenosis was unrelated to sensitivity and technical success (P > 0.05)\[24,25\].

Rotational cine cholangiography is used to diagnose bile duct carcinoma. Rotational cine cholangiography is a reliable technique for detecting the confluence of the bile ducts, as well as for diagnosing the longitudinal extent of cancer spread along the bile duct wall\[26\]. Furukawa \textit{et al.}\[27\] evaluated the usefulness of three-dimensional cholangiography and rotating cine cholangiography for depicting the anatomy of the hilar bile duct and tumor extension, and for planning surgical procedures for hilar cholangiocarcinoma. Three-dimensional and cine cholangiography allowed accurate assessment of the biliary system in patients with hilar cholangiocarcinoma, facilitating the planning of surgery.

**Angiography**

Angiography reveals the anatomy of the hepatic and biliary arteries. Angiography is a superb technique for the detection of vascular encasement. It is also useful for planning surgical procedures.

**Scintigraphy**

Technetium-99m galactosyl human serum albumin scintigraphy: Technetium-99m-diethylenetriaminepentaacetic acid-galactosyl-human serum albumin (99mTc-GSA) is an analog ligand of asialoglycoprotein that binds specifically to asialoglycoprotein receptors (ASGP-R) residing in mammalian hepatocytes\[28-30\]. The hepatic uptake of 99mTc-GSA at 15 min or later reflects the receptor population or functional hepatocyte mass\[31\].

Nanashima \textit{et al.}\[32\] studied the relation between morphological measurements of hepatic volume on CT and functional volume on 99mTc-GSA scintigraphy. There were no significant differences in the volume measurements between these two volumetric techniques. Volumetric measurement by 99mTc-GSA scintigraphy is useful for detecting changes in the functional volume of individual lobes of the liver and is a more dynamic method than the assessment of morphological changes on CT scanning.

We confirmed hemodynamic changes in the distribution of splenic venous flow in the liver, especially in the cirrhotic liver, and demonstrated the participation
of splenic venous flow in the regeneration or enlargement of the hepatic lobe by means of scintiphotosplenopancreatography after percutaneous intrasplenic injection of 99mTc-GSA. We concluded that splenic venous blood flow promotes liver fibrosis in the right lobe of the liver exposed to continuous damage, with gradually increasing flow into the left lobe, showing milder fibrosis.\[59\].

**Positron emission tomography (PET):** PET with [18F]-fluorodeoxyglucose can be used to rule out metastatic disease, although the findings should be interpreted cautiously because of false positive results in inflammatory lesions; moreover a normal PET scan does not exclude cancer.\[30\].

### INITIAL MANAGEMENT

**Biliary drainage**

In patients with obstructive jaundice who have cholangiocarcinoma, especially hilar cholangiocarcinoma, preoperative biliary drainage has been recommended to improve liver function before surgery and to reduce postoperative complications. Percutaneous transhepatic biliary drainage (PTBD) with multiple drains was previously the preferred method for the preoperative relief of obstructive jaundice. In patients with hilar cholangiocarcinoma, drainage is currently performed only for liver lobes that will remain after resection and for areas of segmental cholangitis. Endoscopic biliary drainage (EBD) is less invasive than PTBD. However, EBD has to be converted to PTBD in patients with segmental cholangitis, those requiring prolonged drainage, or those in whom the extent of longitudinal tumor extension is poorly defined.\[60\].

Kamiya et al. reported that impaired intestinal barrier function does not respond to external biliary drainage without bile replacement. Bile replacement during external biliary drainage can restore intestinal barrier function in patients with biliary obstruction, primarily by promoting the repair of physical damage to the intestinal mucosa. Koivukangas et al. reported that cell protein synthesis is disturbed earlier than cell dynamics in obstructive jaundice. Decreased baseline skin-collagen synthesis is partly restored by the resolution of jaundice.\[39\].

We previously reported that elevated serum collagen IV is a feature of malignant obstructive jaundice commonly associated with prolonged bilirubin clearance, and a useful indicator of clinical course, postoperative morbidity, and mortality in patients with malignant obstructive jaundice.\[40\].

The procedure of choice for biliary drainage before major hepatectomy in patients with obstructive jaundice remains controversial, i.e. selective biliary drainage of only the future remnant liver or total biliary drainage. Ishizawa et al. reported that selective biliary drainage is superior to total biliary drainage for promoting hypertrophy of the future remnant liver in patients undergoing portal vein embolization and for guaranteeing good liver function before major hepatectomy. Hochwald et al. showed that preoperative biliary stenting in proximal cholangiocarcinoma increases the incidence of contaminated bile and postoperative infectious complications. Cherqui et al. found that major liver resection without preoperative biliary drainage is a safe procedure in most patients with obstructive jaundice. Recovery of hepatic synthetic function is identical to that of patients without jaundice. Transfusion requirements and the incidence of postoperative complications, especially bile leaks and subphrenic collections, are higher in jaundiced patients. Pitt et al. concluded that preoperative PTBD does not reduce operative risk but does increase hospital costs and, therefore, discouraged routine use. The indication for preoperative biliary stenting in patients with obstructive jaundice remains controversial.

**Portal vein embolization (PVE)**

PVE before hepatectomy is designed to induce atrophy of the embolized lobe scheduled to be resected, while inducing compensatory hypertrophy of preserved lobe.\[39\]. PVE with compensatory contralateral hypertrophy of the future liver remnant has been performed to enable extended hepatectomy (resection of ≥ 5 hepatic segments). We have reported on combined embolization of the hepatic artery and portal vein.\[40\].

**Biliary ablation**

Selective biliary infusion of ethanol can be performed safely without serious complications, inducing lobectomy with contralateral hypertrophy of the liver.\[34\].

**Operation**

Surgical resection has been the mainstay of curative treatment for cholangiocarcinoma. Major hepatectomy with systematic nodal dissection is associated with a good chance of prolonged survival in patients with carcinoma involving the hepatic hilus, including those with advanced disease. Extended hemihepatectomy, with or without pancreateoduodenectomy, plus extrahepatic bile duct resection and regional lymphadenectomy has recently been recognized as the standard curative treatment for hilar bile duct cancer. Pancreateoduodenectomy is the choice of treatment for middle and distal bile duct cancer. Major hepatectomy with pancreateoduodenectomy (hepato pancreatico duodenectomy) has been performed in selected patients with widespread disease. Miyazaki et al. reported that parenchyma-preserving hepatectomy could result in curative resection and improve the outcomes of patients with hilar cholangiocarcinoma localized to the hepatic duct confluence who do not require vascular resection. Less-extensive procedures were also beneficial for less-advanced disease if the resection margins were free of tumor. Even with carefully selected treatment with curative intent, the 5-year survival of patients with cholangiocarcinoma ranges from 30% to 40%. A tumor-free surgical margin is the best predictor of survival. Several staging schemes have been proposed, but none correlates with resectability. Lymph node involvement is also a predictor of survival.\[46,51\].

**Adjuvant therapy**

Neoadjuvant therapy with several types of treatment, including radiation, photodynamic therapy and chemotherapy, provides no clear benefit.\[22,23\].

**Palliative therapy**

Previously, plastic endoprostheses were placed for the
palliative treatment of malignant biliary obstruction. An expandable metal stent (EMS) is used to provide palliation in patients with malignant obstructive jaundice. EMSs have been compared with plastic endoprostheses for the palliative treatment of malignant obstructive jaundice. EMSs are inserted percutaneously or endoscopically.

Biliary stent placement combined with local tumor therapy, such as brachytherapy, extra-radiation therapy, or arterial infusion chemotherapy, can prolong the survival time of patients with malignant biliary obstruction. Mezawa et al. developed a new PTBD tube coated with carboplatin.

Intrahepatic cholangiojejunostomy has been performed in patients with unresectable malignant biliary obstruction. Endoscopic stenting for the management of this condition costs significantly less than surgical treatment. Recently, EUS-guided hepaticojejunostomy has been performed.

Transplantation

Although early survival after transplantation for cholangiocarcinoma is excellent, high recurrence rates have generally discouraged liver replacement. Recent findings, however, have lead to a resurgence in orthotopic liver transplantation for unresectable, albeit locally contained cholangiocarcinoma. Becker et al. reported a series of 280 patients with cholangiocarcinoma who received orthotopic liver transplantation. After a median follow-up of 452 d, the survival rates at 1 and 5 years were 74% and 38%, respectively. Heimbach et al. reported on 56 patients who were treated for unresectable, stage I and II perihilar cholangiocarcinoma. Disease-free survival at 5 years was excellent (82%) in carefully selected patients who underwent neoadjuvant external-beam radiation therapy, transcatheater intrabiliary radiation, chemotherapy, and pretransplant staging exploratory laparotomy. Neoadjuvant chemoradiotherapy with liver transplantation produces excellent results for selected patients with localized, regional node negative, hilar cholangiocarcinoma.

REFERENCES

1. Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol 1983; 139: 217-238
2. Lim JH, Park CK. Pathology of cholangiocarcinoma. Abdom Imaging 2004; 29: 540-547
3. Bloom CM, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics 1999; 19: 1199-1218
4. Smits NJ, Reeder JW. Imaging and staging of biliopancreatic malignancy: role of ultrasound. Ann Oncol 1999; 10 Suppl 4: 20-24
5. Eloubeidi MA, Chen VK, Jhala NC, Eltoum IE, Jhala D, Chhieng DC, Syed SA, Vickers SM, Mel Wilcoz C. Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol 2004; 2: 209-213
6. Fritscher-Ravens A, Broering DC, Striam FP, Topalidis T, Jaeckle S, Thonke F, Soehendra N. EUS-guided fine-needle aspiration cytodiagnosis of hilar cholangiocarcinoma: a case series. Gastrointest Endosc 2000; 52: 534-540
7. Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, Okawa M, Egawa S, Ishibashi T. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg 2007; 14: 434-440
8. Teeley SA, Baron RL, Rohrmann CA, Shuman WP, Freeny PC. Sclerosing cholangitis: CT findings. Radiology 1988; 169: 655-639
9. Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23: 670-677
10. Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Scolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998; 171: 651-658
11. Craenen ME, van Waesberghe JH, van der Peet DL, Loffeld RJ, Cuesta MA, Mulder CJ. Endoscopic ultrasound in patients with obstructive jaundice and inconclusive ultrasound and computer tomography findings. Eur J Gastroenterol Hepatol 2006; 18: 1289-1292
12. Vaishali MD, Agarwal AK, Upadhyaya DN, Chauhan VS, Sharma OP, Shukla VK. Magnetic resonance cholangiopancreatography in obstructive jaundice. J Clin Gastroenterol 2004; 38: 887-890
13. Braga HJ, Iman K, Blumeke DA. MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. AJR Am J Roentgenol 2001; 177: 111-114
14. Petersson MS, Murakami T, Baron RL. MR imaging patterns of gadolinium retention within liver neoplasms. Abdom Imaging 1998; 23: 592-599
15. Lee MG, Park KB, Shin YM, Yoon HK, Sung KB, Kim MH, Lee SG, Kang EM. Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: comparison with intraarterial digital subtraction angiography. World J Surg 2003; 27: 278-283
16. Maguchi H, Takahashi K, Katanuma A, Osanai M, Nakahara K, Matsuzaki S, Urata T, Iwano H. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2007; 14: 441-446
17. Dillon E, Peel AL, Parkin GJ. The diagnosis of primary biliary duct carcinoma (cholangiocarcinoma) in the jaundiced patient. Clin Radiol 1981; 32: 311-317
18. Tsai CC, Mo LR, Chou CY, Han SJ, Lin RC, Kuo JY, Chang KK. Percutaneous transhepatic transluminal forces biopsy in obstructive jaundice. Hepatogastroenterology 1997; 44: 770-773
19. Jung GS, Huh JD, Lee SU, Han BH, Chang HK, Cho YD. Bile duct: analysis of percutaneous transluminal forces biopsy in 130 patients suspected of having malignant biliary obstruction. Radiology 2002; 224: 725-730
20. Savader SJ, Prescott CA, Lund GB, Osterman FA. Intraductal biopsy forces: comparison of three techniques. J Vasc Interv Radiol 1996; 7: 743-750
21. Xing GS, Geng JC, Han XW, Dai JH, Wu CY. Endobiliary brush cytology during percutaneous transhepatic cholangiography in patients with obstructive jaundice. Hepatobiliary Pancreat Dis Int 2005; 4: 98-103
22. Miura F, Asano T, Okazumi S, Takayama Y, Shinohara Y, Makino H, Sugaya M, Ochiai T, Isono K. Rotational cine cholangiography: comparison with intraarterial digital subtraction angiography. Radiology 1983; 147: 111-114
23. Matuzaki S, Urata T, Iwano H. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 1998; 5: 887-890
24. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
25. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
26. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
27. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
28. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
29. Fujita H, Hatakeyama K, Takata H, Tanaka K, Yoshino M, Sakamoto T. Percutaneous biliary drainage for hilar cholangiocarcinoma. Gastrointest Endosc 2000; 52: 534-540
28 Nanashima A, Yamaguchi H, Shibusaki S, Morino S, Ide N, Takeshita H, Tsuji T, Sawai T, Nakagoe T, Nagayasu T, Ogawa Y. Relationship between CT volumetry and functional liver volume using technetium-99m galactosyl serum albumin scintigraphy in patients undergoing preoperative portal vein embolization before major hepatectomy: a preliminary study. *Dig Dis Sci* 2006; 51: 1190-1195

29 Mineta S, Yoshida H, Mamada Y, Tanai N, Mizuguchi Y, Akimaru K, Kumita S, Kumazaki T, Tajiri T. Changes in distribution of splenic venous flow in the patients with cirrhotic liver. *Hepatogastroenterology* 2005; 52: 1313-1319

30 Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer A, Buchert R, Rogiers X, Clausen M. FDG PET in the diagnosis of hilar cholangiocarcinoma. *Nucl Med Commun* 2001; 22: 1277-1285

31 Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. *Ann Surg* 2004; 239: 510-517

32 Kukukanga Y, Okarinen A, Risteli J, Haukipuro K. Effect of jaundice and its resolution on wound re-epithelization, skin collagen synthesis, and serum collagen propeptide levels in patients with neoplastic pancreaticobiliary obstruction. *J Surg Res* 2005; 124: 237-243

33 Mann DV, Lam WW, Magnus Hjelm N, So NM, Yeung DK, Metreweli C, Lau WY. Biliary drainage for obstructive jaundice enhances hepatic energy status in humans: a 31-phosphorus magnetic resonance spectroscopy study. *Gut* 2002; 50: 118-122

34 Mizuguchi Y, Yoshida H, Yokomuro S, Arima Y, Mamada Y, Tanai N, Akimaru K, Tajiri T. Collagen IV is a predictor for clinical course in patients with malignant obstructive jaundice. *Hepatogastroenterology* 2005; 52: 672-677

35 Ishizawa T, Hasegawa K, Sano K, Imamura H, Kokudo N, Makuchi M. Selective versus total biliary drainage for obstructive jaundice caused by a hepatobiliary malignancy. *Am J Surg* 2007; 193: 149-154

36 Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. *Arch Surg* 1999; 134: 261-266

37 Cherqui D, Benoist S, Malassagne B, Humeres R, Rodriguez V, Fagniez PL. Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. *Arch Surg* 2000; 135: 2088

38 Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS. Longmire WP Jr. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? *Ann Surg* 1985; 201: 545-553

39 Takayama T, Makuchi M. Preoperative portal vein embolization: is it useful? *J Hepatobiliary Pancreat Surg* 2004; 11: 17-20

40 Makuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Carver P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. *Surgery* 1990; 107: 521-527

41 Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. *Arch Surg* 2002; 137: 673-680; discussion 680-681

42 Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, Sauvanet A. Portal vein embolization before right hepatectomy: prospective clinical trial. *Ann Surg* 2003; 237: 208-217

43 Mamada Y, Tajiri T, Akimaru K, Yoshida H, Tanai N. Long-term prognosis after arterio-portal embolization for hepatocellular carcinoma. *Hepatogastroenterology* 2004; 51: 234-236

44 Kyokane T, Nagino M, Oda K, Nimura Y. An experimental study of selective intrahepatic biliary ablation with ethanol. *J Surg Res* 2001; 96: 188-196

45 Shimizu T, Yoshida H, Mamada Y, Tanai N, Matsumoto S, Mizuguchi Y, Yokomuro S, Arima Y, Akimaru K, Tajiri T. Postoperative bile leakage managed successfully by intrahepatic biliary ablation with ethanol. *World J Gastroenterol* 2006; 12: 3450-3452

46 Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. *Gut* 2002; 51 Suppl 6: V1-V19

47 Liu CL, Fan ST, Lo CM, Tso WK, Lam CM, Wong J. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. *Br J Surg* 2006; 93: 1488-1495

48 Kosuge T, Yamakawa A, Saito Y, Shimizu Y, Mamada Y, Taniai N, Mizuguchi Y, Shimizu T, Nakagoe T, Nagayasu T, Ogawa Y. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. *Ann Surg* 1999; 230: 663-671

49 Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Okaya T, Shinmura K, Nakajima N. Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma. *J Am Coll Surg* 1999; 189: 575-583

50 Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shinmura K, Okuno A, Nозвa S, Nukui Y, Yoshitomi H, Nakajima N. Segments I and IV resection as a new approach for hepatic hilar cholangiocarcinoma. *Am J Surg* 1998; 175: 229-231

51 Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. *Arch Surg* 2002; 137: 69-73

52 Heron DE, Stein DE, Schelman DJ, Topham AK, Waterman FM, Rosato EL, Alden M, Anne PR. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. *Am J Clin Oncol* 2003; 26: 422-428

53 Serafini FM, Sachs D, Blossom M, Carey LC, Karl RC, Murr MM, Rosemurgy AS. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. *Am J Surg* 2001; 67: 839-843; discussion 843-844

54 Siegel JH, Pullano W, Kodsi B, Cooperman A, Ramsey W. Optimal palliation of malignant bile duct obstruction: experience with endoscopic 12 French prostheses. *Endoscopy* 1988; 20: 137-141

55 Siegel JH, Daniel SJ. Endoscopic and fluoroscopic transpapillary placement of a larger caliber biliary endoprosthesis. *Am J Gastroenterol* 1984; 79: 461-465

56 Coons HG, Carey PH. Large-bore, long biliary endoprostheses (biliary stents) for improved drainage. *Radiology* 1983; 148: 89-94

57 Guoma DJ, Wessendorf RI, Oostenbroek RJ, Soeters PB, Greep JM. Percutaneous transhepatic drainage and insertion of an endoprosthesis for obstructive jaundice. *Am J Surg* 1985; 145: 763-768

58 Men S, Hekimoglu B, Kaderoglu H, Pinar A, Conkbayir I, Soylu SO, Bulut A, Yandaki K, Baran I, Aran Y. Palliation of malignant obstructive jaundice. Use of self-expanding metal stents. *Acta Radiol* 1996; 37: 259-266

59 Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. *Gastrointest Endosc* 2006; 63: 986-995

60 Wagner HJ, Knym R. Relief of malignant obstructive jaundice by endoscopic or percutaneous insertion of metal stents. *Bildgebung* 1993; 60: 76-82

61 Indar AA, Lobo DN, Gilliam AD, Gregson R, Davidson I, Whitaker S, Doran J, Rowlands BJ, Beckingham IJ. Percutaneous biliary metal wall stenting in malignant obstructive jaundice. *Eur J Gastroenterol Hepatol* 2003; 15: 915-919

62 Yoshida H, Mamada Y, Tanai N, Mizuguchi Y, Shimizu T, Yokomuro S, Aimoto T, Nakamura Y, Uchida E, Arima Y, Watanabe M, Uchida E, Tajiri T. One-step palliative treatment method for obstructive jaundice caused by unresectable malignancies by percutaneous transhepatic insertion of an expandable metallic stent. *World J Gastroenterol* 2006; 12: 2423-2426
Tsai CC, Mo LR, Lin RC, Kuo JY, Chang KK, Yeh YH, Yang SC, Yueh SK, Tsai HM, Yu CY. Self-expandable metallic stents in the management of malignant biliary obstruction. *J Formos Med Assoc* 1996; 95: 298-302.

Yoon WJ, Lee JK, Lee KH, Lee WJ, Ryu JK, Kim YT, Yoon YB. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction. *Gastrointest Endosc* 2006; 63: 996-1000.

Kocak Z, Ozkan H, Adli M, Garipagaoglu M, Kurtman C, Cakmak A. Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct. *Radiat Med* 2005; 23: 200-207.

Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. *Hepatogastroenterology* 2004; 51: 954-957.

Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. *Gut* 1996; 39: 852-855.

Hoefvold J, Lunderquist A, Ihse I. Percutaneous transhepatic intubation of bile ducts for combined internal-external drainage in preoperative and palliative treatment of obstructive jaundice. *Gastrointest Radiol* 1978; 3: 23-31.

Mezawa S, Homma H, Sato T, Doi T, Miyarnishi K, Takada K, Kukitsu T, Murase K, Yoshizaki N, Takahashi M, Sakamaki S, Niitsu Y. A study of carboplatin-coated tube for the unresectable cholangiocarcinoma. *Hepatology* 2000; 32: 916-923.

Suzuki S, Kurachi K, Yokoi Y, Tsuchiya Y, Okamoto K, Okumura T, Inaba K, Konno H, Nakamura S. Intrahepatic cholangiojejunostomy for unresectable malignant biliary tumors with obstructive jaundice. *J Hepatobiliary Pancreat Surg* 2001; 8: 124-129.

Guthrie CM, Banting SW, Garden OJ, Carter DC. Segment III cholangiojejunostomy for palliation of malignant hilar obstruction. *Br J Surg* 1994; 81: 1639-1641.

Traynor O, Castaing D, Bismuth H. Left intrahepatic cholangio-enteric anastomosis (round ligament approach): an effective palliative treatment for hilar cancers. *Br J Surg* 1987; 74: 952-954.

Martin RC 2nd, Vitale GC, Reed DN, Larson GM, Edwards MJ, McMasters KM. Cost comparison of endoscopic stenting vs surgical treatment for unresectable cholangiocarcinoma. *Surg Endosc* 2002; 16: 667-670.

Bories E, Pesenti C, Caillol F, Lopes C, Giovannini M. Transgastric endoscopic ultrasonography-guided biliary drainage: results of a pilot study. *Endoscopy* 2007; 39: 287-291.

Becker NS, Rodriguez JA, Barshes NR, O’Mahony CA, Goss JA, Aloia TA. Outcomes Analysis for 280 Patients with Cholangiocarcinoma Treated with Liver Transplantation Over an 18-year Period. *J Gastrointest Surg* 2008; 12: 117-122.

Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. *Semin Liver Dis* 2004; 24: 201-207.

Thelen A, Neuhaus P. Liver transplantation for unresectable hilar cholangiocarcinoma. *J Hepatobiliary Pancreat Surg* 2007; 14: 469-475.